This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Change in Brain Metabolism and Cognitive Function by Aripiprazole

This study has been completed.
Information provided by (Responsible Party):
Jun Soo Kwon, Seoul National University Hospital Identifier:
First received: March 22, 2012
Last updated: March 23, 2012
Last verified: March 2012

Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.

The investigators explored the relationship between changes in brain metabolism and working memory performance.

Condition Intervention
Antipsychotics Cognition Brain Metabolism Dopamine Receptor Occupancy Drug: Aripiprazole

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Relationship Between D2 Occupancy and Change in Frontal Metabolism and Working Memory Induced by Aripiprazole

Resource links provided by NLM:

Further study details as provided by Jun Soo Kwon, Seoul National University Hospital:

Primary Outcome Measures:
  • Reaction time of correct response in N-back task [ Time Frame: 48 hrs after the administration of aripiprazole ]

Enrollment: 15
Study Start Date: January 2009
Study Completion Date: January 2012
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Aripiprazole
    single oral administration of aripiprazole

Ages Eligible for Study:   19 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy volunteers
  • right-handed

Exclusion Criteria:

  • any significant abnormality on routine lab
  • any psychiatric disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01562808

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Jun Soo Kwon, M.D., Ph.D. Seoul National University Hospital
  More Information

Responsible Party: Jun Soo Kwon, Professor, Seoul National University Hospital Identifier: NCT01562808     History of Changes
Other Study ID Numbers: A070001
Study First Received: March 22, 2012
Last Updated: March 23, 2012

Additional relevant MeSH terms:
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on September 21, 2017